“When administered 24 h after OVA, budesonide , a glucocorticosteroid, or 4‐(8‐benzo[1,2,5]oxadiazol‐5‐yl‐[1,7]naphthyridin‐6‐yl)‐benzoic acid (NVP‐ABE171), a selective phosphodiesterase 4 inhibitor, increased the rate of resolution of established oedematous signals detected by MRI.”